Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock Short Interest Report for October

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large decrease in short interest in October. As of October 15th, there was short interest totaling 126,324 shares, a decrease of 38.3% from the September 30th total of 204,583 shares. Based on an average trading volume of 354,271 shares, the short-interest ratio is currently 0.4 days. Currently, 15.0% of the company’s stock are sold short.

Analyst Ratings Changes

A number of research firms have commented on MBRX. HC Wainwright cut their target price on shares of Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $60.00.

Moleculin Biotech Trading Up 5.3%

Shares of NASDAQ:MBRX traded up $0.42 on Monday, reaching $8.32. The company had a trading volume of 12,949 shares, compared to its average volume of 33,729. Moleculin Biotech has a 52-week low of $3.23 and a 52-week high of $315.00. The firm’s 50 day simple moving average is $10.84 and its 200-day simple moving average is $40.73. The firm has a market capitalization of $8.57 million, a PE ratio of -1.17 and a beta of 2.11.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($28.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($31.00) by $3.00. As a group, equities research analysts predict that Moleculin Biotech will post -47.40 earnings per share for the current year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.